Home/Pipeline/REGN7075 + Libtayo

REGN7075 + Libtayo

Colorectal Cancer

Phase 1/2ActiveN/A

Key Facts

Indication

Colorectal Cancer

Phase

Phase 1/2

Status

Active

Company

Regeneron Pharmaceuticals

About Regeneron Pharmaceuticals

Regeneron is a premier biotechnology company with a mission to translate groundbreaking science into life-changing medicines for patients. Its achievements are anchored by its proprietary VelociSuite® technology platforms, which have enabled the development of a robust commercial portfolio and one of the industry's deepest pipelines. The company's strategy combines sustained internal R&D investment with selective, high-value collaborations, all supported by a fully integrated model from discovery to global commercialization.

View full company profile

Therapeutic Areas

Ophthalmology Cardiovascular & Metabolic Diseases Oncology & Hematology Allergic & Inflammatory Diseases Rare Diseases Infectious Diseases Neuroscience Pain

Other Colorectal Cancer Drugs

Drug	Company	Phase	Status
CY-101 + Pembrolizumab	Cytovation	Phase 1/2	Initiate 1H-26
Leronlimab	CytoDyn	Phase 2	Phase in progress
EGFR inhibitor	Acellera	Pre-clinical	Hit Identification
VCR-036	Vicero Bio	Preclinical	Active
CBI-1214	Cartography Biosciences	Phase 1	Active
QL335	QLSF Biotherapeutics	Phase 1	Active
Colorectal Cancer Detection Partnership	Daisy Genomics	Research/Assay Development	Active
High Internalization ADC	Lytica Therapeutics	Preclinical	Active
Undisclosed Colorectal Program(s)	Tavanta Therapeutics	Phase 2	Active
KRAS AK™PCR Mutation Screen Kit	Akcell Biotech	Commercial	Active
Program not named	Reponex	Pre-clinical	Active
Colorectal Cancer Screening Test	Metabiomics	Approved	Active